Targeted Drug Delivery System for Cardiovascular Diseases Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1273

Special Issue Editors


E-Mail Website
Guest Editor
Laboratory for Vascular Translational Science, Cardiovascular Bioengineering, Université Sorbonne Paris Nord-INSERM U1148, 99 Av. Jean-Baptiste Clément, 93430 Villetaneuse, France
Interests: nanotechnology; lipid formulations; drug delivery; drug targeting; cellular models; animal models; oxidative stress; antioxidants
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Laboratory of Cardiovascular Pharmacology (LaFaC), Federal University of Grande Dourados (UFGD), Rodovia Dourados-Itahum, km 12, P.O. Box 533, Dourados 79.804-970, MS, Brazil
Interests: antihypertensive; antiatherogenic; cardioprotective; diuretic; lipid-lowering; vasodilator
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiovascular diseases (CVD) are the main causes of illness and death globally. Hypertension is the leading risk factor that exacerbates the occurrence, seriousness, and advancement of different types of cardiovascular diseases, which include arteriosclerosis and thrombosis. The association between hypertension, arteriosclerosis and other cardiovascular disorders increases the risk of undesirable outcomes in different patient groups. There are various options available for treating CVD, including synthetic drugs and herbal medicines. However, numerous compounds and extracts have not yet undergone thorough scientific investigation in terms of drug delivery, drug dosage forms, and pharmaceutical formulations. As a result, there is a requirement for systematic endeavors to establish the effectiveness and safety of these formulations.

In this Special Issue, we invite researchers to submit studies on drug dosage form design, targeted drug delivery, pharmacokinetics, and biopharmaceutics focusing on advancements in the treatment of cardiovascular diseases. We gladly accept both original research and review articles. Potential submission topics may include, but are not restricted to:

  • Dosage forms and drug delivery systems;
  • Characterization of biopharmaceutical formulations;
  • Standardization and evaluation of herbal drug formulations;
  • Quality control in drug development;
  • Excipient–drug interactions;
  • Pharmacokinetics studies in drug discovery.

Dr. Graciela Pavon-Djavid
Dr. Arquimedes Gasparotto Junior
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • biopharmaceutical
  • quality control
  • cardioprotection
  • hypertension
  • drug development
  • arteriosclerosis
  • thrombosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 2145 KiB  
Article
NO-cGMP-K+ Channels Pathways Participate in the Antihypertensive Effects of Attalea phalerata Martius ex Spreng Oil-Loaded Nanocapsules
by Maria Medina de Azevedo, Francislaine Aparecida dos Reis Lívero, Sílvia Beatriz Bürger Tinelli, Jacenir Vieira da Silva, Danielle Ayr Tavares de Almeida, Marco Antonio Utrera Martines, Ariadna Lafourcade Prada, Jesús Rafael Rodríguez Amado and Arquimedes Gasparotto Junior
Pharmaceutics 2024, 16(7), 842; https://doi.org/10.3390/pharmaceutics16070842 - 21 Jun 2024
Viewed by 834
Abstract
Attalea phalerata Martius ex Spreng is a palm tree that is widely distributed in the Central-West region of Brazil. In this study, we investigated whether the oil-loaded nanocapsules of A. phalerata (APON) have acute and long-lasting antihypertensive effects in male spontaneously hypertensive rats [...] Read more.
Attalea phalerata Martius ex Spreng is a palm tree that is widely distributed in the Central-West region of Brazil. In this study, we investigated whether the oil-loaded nanocapsules of A. phalerata (APON) have acute and long-lasting antihypertensive effects in male spontaneously hypertensive rats (SHR), as well as explored the underlying molecular mechanisms. APON was prepared using the interfacial polymer deposition method. The particle size, polydispersity index, and zeta potential were investigated using dynamic and electrophoretic light scattering. The antihypertensive effects of APON (administered at doses of 1, 3, and 10 mg/kg) were evaluated after acute intraduodenal administration and after 7 days of oral treatment. To investigate the molecular pathways involved, we used pharmacological antagonists and inhibitors that target prostaglandin/cyclic adenosine monophosphate, nitric oxide/cyclic guanosine monophosphate, and potassium channels. Both acute and prolonged administration of APON (at doses of 3 and 10 mg/kg) resulted in a significant reduction in systolic, diastolic, and mean arterial pressure. Prior treatment with a non-selective nitric oxide synthase inhibitor (Nω-nitro-L-arginine methyl ester), guanylyl cyclase inhibitor (methylene blue), or non-selective calcium-sensitive K+ channel blocker (tetraethylammonium) abolished the antihypertensive effects of APON. Our study showed that A. phalerata oil-loaded nanocapsules have a significant antihypertensive effect in SHR after both short-term and long-term (7-day) use. This effect seems to rely on the vascular endothelium function and involves the NO-cGMP-K+ channel pathway. This research suggests a new direction for future studies to definitively prove the therapeutic benefits of APON in treating cardiovascular disease. Full article
(This article belongs to the Special Issue Targeted Drug Delivery System for Cardiovascular Diseases Treatment)
Show Figures

Figure 1

Back to TopTop